NCT02225002View on ClinicalTrials.gov

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2004

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Advanced Solid Tumors
Interventions
DRUG

CP-870,893

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02225002 - Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter